PLAINSBORO, N.J., May 1, 2009 (GlobeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) will feature the OSVII Low Pro(TM) Valve, a low profile version of the OSVII(R) Flow-Controlled Hydrocephalus Valve, at the American Association of Neurological Surgeons Annual Meeting in San Diego, California, May 2-6, 2009. The Integra OSVII Low Pro(TM) Valve is Integra's newest implantable shunt used in the treatment of hydrocephalus, and was designed with a lower profile to accommodate various patient populations, particularly pediatric patients.

Integra's OSVII(R) Valves are a revolutionary advancement in the treatment of hydrocephalus. They are designed to drain cerebrospinal fluid (CSF) from the ventricles of the brain at a constant rate of flow, close to that of normal CSF production, thereby minimizing the risks of under or overdrainage. To achieve a constant rate of flow under a wide range of conditions, the OSVII(R) Valves are automatically self-adjusting and adapt to the patient's changing physiological requirements without the necessity for external reprogramming.

The OSVII(R) and OSVII Low Pro(TM) Valves have three modes of operation: in normal operation, the valves act to maintain a CSF flow rate within a range of 18-30 ml/hour; during periods of very low intracranial pressure (ICP), they act as normal differential pressure valves; and in the event of a sudden increase in ICP, the valves shift operation to a safety mode stage, allowing a high flow rate until ICP returns to within a normal range.

Hydrocephalus is a condition in which the primary characteristic is excessive accumulation of CSF in the brain. To maintain a normal level of CSF within the ventricles, hydrocephalus is most commonly treated by inserting a shunt into the ventricular system, allowing CSF to flow out of the brain via a pressure-flow valve system to an appropriate drainage site, such as the peritoneal cavity or the right atrium of the heart

Each year there are approximately 50,000 new and revision cases that receive shunts for the treatment of hydrocephalus. According to industry sources, the total U.S. market for hydrocephalus management is estimated at over $100 million.

Integra currently offers an extensive range of hydrocephalus management products, including the OSVII(R) and Integra NPH(TM) flow-controlled valves, Integra DP(TM), Equi-Flow(TM), Novus(TM), LPVII(TM), Pudenz(TM) and H-V Lumbar Valves, as well as ventricular, lumbar, peritoneal and cardiac catheters.

The OSVII Low Pro(TM) Valve Systems are sold in the U.S.A. and Europe through the Integra NeuroSciences direct sales organization. Integra NeuroSciences is a leading provider of implants, devices, instruments and systems used in neurosurgery, neuromonitoring, neuro-trauma, and related critical care. Integra NeuroSciences' direct selling effort in the United States and Europe involves more than 200 direct sales professionals. In all other markets, Integra NeuroSciences products are sold through a network of distributors.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of clinically relevant, innovative, and cost-effective surgical implants and medical instruments. Integra's products, used primarily in neurosurgery, orthopedics and general surgery, are used to treat millions of patients every year. The company's headquarters are in Plainsboro, New Jersey, and it has research and manufacturing facilities throughout the world. For more information visit www.Integra-LS.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of Integra products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in section IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2008 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART-P

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation
          Gianna Sabella, Director of Corporate Communications
          (609) 936-2389
          gsabella@integra-LS.com

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX